See Why Cellect Biotechnology Stock Is Soaring During Premarket Friday
Cellect Biotechnology Ltd (NASDAQ:APOP) announced the first ApoGraft transplantation in a Leukemia patient in a clinical trial in the U.S. ApoGraft…
The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 2)
20 Stocks Moving in Friday’s Pre-Market Session
Gainers
Cellect Biotechnology Ltd. (NASDAQ: APOP) rose 59.5% to $8.77 in pre-market trading after the company announced the ApoGraft bone marrow transplantation of the first patient in the US.
Cellect Biotechnology Announces the ApoGraft™ Bone Marrow Transplantation of First Patient in U.S.
Reflecting continued clinical progress, Cellect Biotechnology Ltd. (NASDAQ: "APOP"), announced the first ApoGraftTM transplantation in a Leukemia patient in the Company's clinical trial at Washington
48 Biggest Movers From Yesterday
Gainers
RenovoRx, Inc. (NASDAQ: RNXT) climbed 107.8% to close at $16.02 on Monday after the company was granted FDA clearance for ‘Catheter, Intravascular Occluding, Temporary.’ The company recently priced its IPO at $9 per unit.
Cellect Biotechnology Q2 EPS $(0.004) Up From $(0.007) YoY
Cellect Biotechnology (NASDAQ:APOP) reported quarterly losses of $(0.00) per share. This is a 42.86 percent increase over losses of $(0.01) per share from the same period last year.
